Project Name: Croydon Rapid optimisation Clinic

Project Summary: 

This CWP aims to improve the current hospital-based specialist HF service provided by the CW Partner by creating 2 additional clinics per week run by a Band 7 Heart Failure Specialist Nurse (“HFSN”) and/or Band 7 Specialist Pharmacist with an additional 6 hours administration support per week. These clinics will enable patients recently discharged or are new outpatient referrals, to be seen quickly and started on optimal heart failure medication combinations. Optimising HF patients’ treatment regimes is associated with improved patient QOL and reduced HF hospitalisations. A reduction in waiting times and improved efficiency in lipid optimizing patients will bring the CW Partner in line with other centres in the country. Additionally, CW Partner will establish a business case for future funding of this extension to the Heart Failure (HF) service by the NHS.

Planned Milestones:

CW Partner: Collection of baseline data, in line with the Project Outcome Measures & Data Collection table.

CW Partner: Confirmation of clinical and operational pathway, policy and protocol creation, and readiness to begin the clinical activity (CW Partner shall ensure that the clinical staff covered by the Novartis Financial Contribution are in place, trained and ready to begin clinical activity). Hire purchase  of blood pressure  machines. 

CW Partner: Collection & submission of [3] months clinical activity data. CW Partner and Novartis: Project Review meeting to discuss project progress.

CW Partner: Collection & submission of [6] months clinical activity data. CW Partner and Novartis: Project Review meeting to discuss project progress.

CW Partner: Collection & submission of [9] months clinical activity data. CW Partner and Novartis: Project Review meeting to discuss project progress.

CW Partner: Collection & submission of [12] months clinical activity data. CW Partner and Novartis: Project Review meeting to discuss project progress.

CW Partner: Development of business case, submission of business case by the CW Partner team to relevant body within the NHS Board and submit final CWP report to Novartis within 2 months completion of the clinical work.

Expected Benefits:

Anticipated benefits for Patients 

  • Improved access to evidence based treatment;
  • Increased  equitable and consistent care and access to care.
  • Enhanced experience for patients and their carers who live with HF

Anticipated benefits for the CW Partner

  • Increase the overall quality of care and improve equity of access to specialist care for patients with HF;
  • Increase proportion of patients with HF being managed in accordance with the ESC 2021 chronic heart failure guidelines
  • Reduction in waiting list times 

Anticipated Benefits For Novartis

  • Further opportunities for the appropriate use of cardiology licensed medicines in line with NICE guidelines, including Novartis’s medicine;
  • Improved reputation;Improved professional and transparent relationship and trust between Novartis and the NHS
  • Better understanding of overall customers’ and patients’ needs;

Start Date & Duration: June 2024 for 16 months

UK2402211327